BMPR1B

Across TCGA pan-cancer cohorts, BMPR1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BMPR1B data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher BMPR1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMPR1B expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

PAAD, UCEC, and COAD are the cancer types where BMPR1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →
UCEC	DFS	Median	All	1.000	0.636	.040	4	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →
BLCA	DFS	Median	III,IV	1.000	0.299	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BMPR1B–PAAD (DFS)

Open the PAAD breakdown →